Bial Shelves the BIA 28-6156 Parkinson Phase 2 Trial After the Trofa Pharma Reads No Efficacy Signal at the Primary Endpoint — Five-Year Disease-Modification Programme Folded as the Compound Misses Its Placebo Comparator

Bial-Portela & C. (Bial), the Trofa-based family-owned pharmaceutical company that remains Portugal's largest independent drug developer, confirmed on Monday 9 June 2026 that it has discontinued the clinical development of BIA 28-6156, the disease-modifying compound it had taken into a Phase 2 trial for Parkinson's disease (doença de Parkinson). The company released a brief institutional statement to ECO and to the Portuguese trade health press the same afternoon, with CEO António Portela framing the outcome of the Phase 2 read-out as "disappointing" but consistent with the inherent risk profile of central-nervous-system (CNS) drug development.

What the Phase 2 Read-Out Said

The Phase 2 study — a randomised, double-blind, placebo-controlled trial running across multiple sites in Europe and North America — was designed to test whether BIA 28-6156 could meaningfully slow disease progression in patients with early Parkinson's disease carrying glucocerebrosidase (GBA1) gene variants. Bial's communiqué said the read-out "did not demonstrate a statistically significant difference relative to placebo in the primary endpoint and in the main secondary endpoints," closing the door on the original hypothesis that the molecule could deliver a disease-modifying signal in this enriched genetic subpopulation. The company added that the safety profile observed during the trial was acceptable and that no new safety signals emerged — a clean read on tolerability is small consolation when efficacy fails, but it keeps the door open for the underlying chemistry to be re-purposed in adjacent indications down the line.

How the Compound Got Here

BIA 28-6156 had been one of Bial's flagship development assets since the company first disclosed it had advanced into Phase 1 in 2021 and through Phase 2 dosing from 2024. The compound was a glucocerebrosidase-targeting small molecule — a mechanism that the broader pharma sector still considers one of the most promising biological pathways for genetically defined Parkinson's, alongside the more advanced LRRK2 programmes pursued by competitors such as Denali Therapeutics and Biogen. Bial reported "marco operacional" (operational milestone) progress on the trial in January 2026 and Bial then-CEO had publicly described the asset as the company's most ambitious R&D bet outside the already-approved Opicapone (Ongentys) symptom-management franchise.

Opicapone Franchise Stays Intact

Crucially, the BIA 28-6156 discontinuation does not touch Bial's commercial Parkinson's portfolio. Opicapone — the catechol-O-methyltransferase (COMT) inhibitor sold under the brand Ongentys — was approved by the European Medicines Agency (EMA) in 2016 and by the United States Food and Drug Administration (FDA) in 2020 as an adjunct to levodopa-carbidopa therapy in adult patients experiencing end-of-dose motor fluctuations. Opicapone remains Bial's first home-grown molecule to reach commercial scale in the United States and Europe and continues to be the engine of the company's growth in the symptom-management Parkinson's space. The shelved Phase 2 candidate was, by contrast, an entirely separate disease-modifying chemistry that would have addressed disease progression rather than symptom control.

What Falls Out of the Pipeline

Independent equity research desks covering the Portuguese pharma sector had baked BIA 28-6156 risk-adjusted contribution into Bial's long-run development matrix at roughly the low-hundreds of millions of euros in peak-sales potential, conditional on positive Phase 2 data. With the readout absent, that probabilistic line item now rotates to zero and the implied near-term R&D expense reduction freeing up Phase 3 spend that would have begun late 2026 or early 2027 if the Phase 2 had succeeded. The company has not yet disclosed how much of the Phase 2 spend has already been booked or how the freed development envelope will be redeployed. Bial has previously flagged additional preclinical and early-clinical Parkinson's assets in its disclosed pipeline, alongside CNS programmes in epilepsy (where Aptiom/Eslicarbazepine remains an FDA-approved asset) and a chronic-pain franchise — that broader portfolio is unaffected by Monday's announcement.

What This Means for the Portuguese Life-Sciences Tape

Bial sits at the head of the Portuguese pharma sector by R&D spend, accounting for a disproportionate share of the country's industrial-pharma research outlay. The Health Cluster Portugal and AICEP's life-sciences trade-promotion teams have long pointed to Bial's Trofa research campus as the country's clearest example of an end-to-end small-molecule pipeline run out of Portugal. A failed Phase 2 in a high-risk indication is not, by itself, a reflection on the country's broader life-sciences narrative — Phase 2 attrition rates in CNS run materially above the cross-therapeutic 30% average — but the discontinuation does take some shine off the headline-grabbing development story that Portuguese pharma had been pointing investors toward. Domestic biotech-startup desks at NOVA Medical School, the i3S Porto institute and the Champalimaud Foundation have publicly noted that the discontinuation underscores the structural difficulty of running disease-modifying CNS programmes from a mid-size pharma without deep multinational pocket — a reminder that even Bial-scale Portuguese research operations face the same coin-flip biology that the global majors do.

What This Means for Expats

• Treatment access stays unchanged: Ongentys (Opicapone) remains comparticipated by the Serviço Nacional de Saúde (SNS, National Health Service) under the standard 37% co-payment in the General Reimbursement Regime for Parkinson's patients with end-of-dose motor fluctuations. Patients prescribed Opicapone in 2026 are unaffected by the BIA 28-6156 shelving.
• Clinical-trial enrolment channels: Expats considering enrolment into Phase 2/3 Parkinson's trials hosted at Portuguese sites should redirect enquiries to the Champalimaud Foundation's neurology-trial coordinator, the Faculdade de Medicina da Universidade do Porto (FMUP) movement-disorders unit, and the Hospital Egas Moniz neurology-research team in Lisboa, which run alternative compound trials sponsored by other developers.
• Pharma-sector employment: Bial's Trofa research site employs more than 800 people, with the broader Bial group nudging 2,000 — the BIA 28-6156 discontinuation does not, on its own, signal a workforce step-down, but expats working in Portuguese pharma R&D should watch the upcoming Bial annual-results communication (typically March/April) for any redeployment signals on the early-clinical CNS bench.
• Listed-equity exposure: Bial is unlisted (family-owned), so retail equity exposure is not available on the Euronext Lisbon. Expats with portfolio interest in the Portuguese pharma sector can take indirect exposure via Galenica's parent-group exposures, via the PSI generally for adjacent biotech reads, or via Iberian healthcare ETFs.
• R&D-incentive landscape: Portugal's SIFIDE II tax-credit regime for corporate R&D — relevant to expat founders running pharma-startup operations from Portugal — remains the load-bearing instrument and is unaffected by the Bial readout; the regime continues to scale credit at 32.5% baseline and up to 50% on the incremental component over the previous two-year average.

Bial said it will continue to monitor the safety follow-up window on the discontinued cohort per standard Phase 2 protocol obligations and that the company "remains committed to the development of treatments capable of altering the progression of Parkinson's disease." Whether that commitment translates into a follow-on disease-modifying chemistry, a partnership deal on an in-licensed candidate, or a wider strategic pivot away from disease-modification toward symptom-control reinforcement will be the through-line investors and the Portuguese biotech community read for in the next twelve months.